Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated ...

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) will likely be announcing its earnings results before the market opens on ...

It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...

CELEBRATION, Fla. — CELEBRATION, Fla. — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter. The Celebration, Florida-based company said it had a loss of ...

Analysts at Roth Capital decreased their FY2029 EPS estimates for shares of Zevra Therapeutics in a report issued on Tuesday, ...

The latest price target for Zevra Therapeutics (NASDAQ:ZVRA) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $25.00 expecting ZVRA to rise to within 12 ...